Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Protein Kinase Inhibitors"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 2761
Tytuł:
Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation.
Autorzy:
Wang S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Xu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Pan C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Guo Q; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Li Q; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Wan S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Li Z; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Zhang J; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Wu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 04; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/isolation & purification
Antineoplastic Agents*/pharmacology
ErbB Receptors*/antagonists & inhibitors
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/isolation & purification
Protein Kinase Inhibitors*/pharmacology
Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Cell Line, Tumor ; Cell Proliferation ; Lung Neoplasms/drug therapy ; Molecular Docking Simulation ; Molecular Dynamics Simulation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer.
Autorzy:
Chang CD; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chao MW; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.; Institute of Biopharmaceutical Sciences, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
Lee HY; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.
Liu YT; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Tu HJ; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Lien ST; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Lin TE; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Sung TY; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
Yen SC; Warshel Institute for Computational Biology, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, People's Republic of China.
Huang SH; Graphen Inc, New York, NY, USA.
Hsu KC; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan.; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Pan SL; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2166039.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/enzymology
Protein Serine-Threonine Kinases*/antagonists & inhibitors
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Humans ; Cell Line, Tumor ; Gemcitabine/chemistry ; Gemcitabine/pharmacology ; Intracellular Signaling Peptides and Proteins ; Computer Simulation ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations.
Autorzy:
Malarz K; Institute of Physics, University of Silesia in Katowice, Chorzów, Poland.
Mularski J; Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.
Pacholczyk M; Department of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland.
Musiol R; Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2201410.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/chemistry
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/chemistry
Molecular Docking Simulation ; Quinazolines/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Autorzy:
Fakhry MM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt.
Mattar AA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt.
Alsulaimany M; Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina 42353, Saudi Arabia.
Al-Olayan EM; Department of Zoology, College of Science, King Saud University, Riyadh 11495, Saudi Arabia.
Al-Rashood ST; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abdel-Aziz HA; Applied Organic Chemistry Department, National Research Center, Cairo 12622, Egypt.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Nov 06; Vol. 28 (21). Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/chemistry
Antineoplastic Agents*/chemistry
Humans ; Molecular Structure ; Structure-Activity Relationship ; Lapatinib/pharmacology ; Drug Screening Assays, Antitumor ; Cell Proliferation ; ErbB Receptors/metabolism ; Molecular Docking Simulation ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation.
Autorzy:
Florio A; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Johnson S; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Salvatori R; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Vasmatzis G; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. .; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 27; Vol. 14 (1), pp. 7303. Date of Electronic Publication: 2024 Mar 27.
Typ publikacji:
Journal Article
MeSH Terms:
MicroRNAs*/metabolism
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Antineoplastic Agents*/pharmacology
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Humans ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Feedback ; ErbB Receptors/metabolism ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Drug Resistance, Neoplasm ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021-Present).
Autorzy:
Abdel-Mohsen HT; Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, Cairo P.O. Box 12622, Egypt.
Anwar MM; Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, Cairo P.O. Box 12622, Egypt.
Ahmed NS; Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, Cairo P.O. Box 12622, Egypt.
Abd El-Karim SS; Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, Cairo P.O. Box 12622, Egypt.
Abdelwahed SH; Department of Chemistry, Prairie View A & M University, Prairie View, TX 77446, USA.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Feb 16; Vol. 29 (4). Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents*/chemistry
Neoplasms*/drug therapy
Neoplasms*/metabolism
Humans ; Quinazolines/pharmacology ; Quinazolines/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Drug Design ; Protein Kinases/metabolism ; Structure-Activity Relationship ; Molecular Docking Simulation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of A Novel Series of Quinazoline-Thiazole Hybrids as Potential Antiproliferative and Anti-Angiogenic Agents.
Autorzy:
Șandor A; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 41 Victor Babes, Street, 400010 Cluj-Napoca, Romania.
Fizeșan I; Department of Toxicology, Faculty of Pharmacy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Ionuț I; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 41 Victor Babes, Street, 400010 Cluj-Napoca, Romania.
Marc G; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 41 Victor Babes, Street, 400010 Cluj-Napoca, Romania.
Moldovan C; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 41 Victor Babes, Street, 400010 Cluj-Napoca, Romania.
Oniga I; Department of Pharmacognosy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 12 Ion Creangă Street, 400010 Cluj-Napoca, Romania.
Pîrnău A; National Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donath Street, 400293 Cluj-Napoca, Romania.
Vlase L; Department of Pharmaceutical Technology and Biopharmaceutics, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 41 Victor Babeș, Street, 400012 Cluj-Napoca, Romania.
Petru AE; Department of Toxicology, Faculty of Pharmacy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Macasoi I; Department of Toxicology, Faculty of Pharmacy, 'Victor Babeș' University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania.; Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, 'Victor Babes' University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania.
Oniga O; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 41 Victor Babes, Street, 400010 Cluj-Napoca, Romania.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2024 Feb 12; Vol. 14 (2). Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/chemistry
Sorafenib/pharmacology ; Molecular Docking Simulation ; Quinazolines/pharmacology ; Quinazolines/chemistry ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Angiogenesis Inhibitors/pharmacology ; Cell Proliferation ; Molecular Structure
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tenovin 3 induces apoptosis and ferroptosis in EGFR 19del non small cell lung cancer cells.
Autorzy:
Lv S; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Pan Q; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Lu W; The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Heyuan, 517000, China.
Zhang W; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Wang N; GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Huang L; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Li L; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Liu J; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Ma J; Medicine and Health Science College, Guangzhou Huashang College, Guangzhou, People's Republic of China.
Li Z; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Huang Y; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Deng Q; GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China. .
Lei X; The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Apr 01; Vol. 14 (1), pp. 7654. Date of Electronic Publication: 2024 Apr 01.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Ferroptosis*
Humans ; ErbB Receptors/metabolism ; Apoptosis ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Protein Kinase Inhibitors/pharmacology ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Design, Synthesis, Biological Evaluation and Molecular Docking of Novel F-18-Labeled Focal Adhesion Kinase Inhibitors as Potential Tumor Radiotracers.
Autorzy:
Yang H; Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, China.
Li Y; Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, China.
Liang H; Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, China.
Cui C; Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, China.
Gan L; Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, China.
Zhang H; Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Mar 08; Vol. 29 (6). Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*/diagnostic imaging
Neoplasms*/drug therapy
Antineoplastic Agents*/chemistry
Mice ; Animals ; Focal Adhesion Protein-Tyrosine Kinases ; Molecular Docking Simulation ; Radiopharmaceuticals/chemistry ; Biological Transport ; Protein Kinase Inhibitors/chemistry ; Cell Line, Tumor ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia
Autorzy:
Tokatlı M; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Türkiye
Ismayilov R; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Türkiye
Erkin Çınar O; Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Türkiye
Haznedaroğlu İC; Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Türkiye
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 59-60. Date of Electronic Publication: 2023 Dec 28.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/complications
Leukemia, Myeloid*/complications
Antineoplastic Agents*/adverse effects
Leukemia, Myeloid, Chronic-Phase*/complications
Humans ; Constriction, Pathologic/complications ; Pyrimidines/adverse effects ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.
Autorzy:
Zhou S; Division of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China, Xiangya road 87.
Abdihamid O; Garissa Cancer Center, Garissa County Referral Hospital, Kismayu road, Garissa town, P.O BOX, 29-70100, Kenya.
Tan F; Division of Surgery, Xiangya Hospital, Central South University, China, Hunan, Changsha.
Zhou H; Division of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Liu H; Division of Surgery, Xiangya Hospital, Central South University, China, Hunan, Changsha.
Li Z; Center for Molecular Medicine of Xiangya Hospital, Collaborative Innovation Center for Cancer Medicine, Central South University, Changsha, Hunan, China, 410008.
Xiao S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, 410008, MA, USA.
Li B; Division of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China, Xiangya road 87#. .
Pokaż więcej
Źródło:
Cell communication and signaling : CCS [Cell Commun Signal] 2024 Feb 27; Vol. 22 (1), pp. 153. Date of Electronic Publication: 2024 Feb 27.
Typ publikacji:
Video-Audio Media; Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Gastrointestinal Stromal Tumors*/drug therapy
Gastrointestinal Stromal Tumors*/genetics
Gastrointestinal Stromal Tumors*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Biological Products*
Humans ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; Epigenesis, Genetic ; Pyrimidines ; Proto-Oncogene Proteins c-kit/genetics ; Proto-Oncogene Proteins c-kit/metabolism ; Mutation/genetics ; Drug Resistance, Neoplasm/genetics ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study.
Autorzy:
Chen J; Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China.
Zheng Q; Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China.
Zhu S; Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China.
Qiu D; Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China.
Wang J; Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 20; Vol. 14 (1), pp. 4165. Date of Electronic Publication: 2024 Feb 20.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Antineoplastic Agents*/therapeutic use
Humans ; Retrospective Studies ; Neutrophils ; Immune Checkpoint Inhibitors/therapeutic use ; Prognosis ; Lymphocytes ; ErbB Receptors ; Mutation ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Autorzy:
Shan KS; Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USA.
Bonano-Rios A; Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USA.
Theik NWY; Division of Internal Medicine, Memorial Health Care, Pembroke Pines, FL 33028, USA.
Hussein A; Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USA.
Blaya M; Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 06; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Neoplasms*/drug therapy
Neoplasms*/chemically induced
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Phosphatidylinositol 3-Kinase/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; TOR Serine-Threonine Kinases/metabolism ; Molecular Targeted Therapy ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Carcinogenesis/chemically induced ; Phosphatidylinositols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.
Autorzy:
Frumento D; Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.
Grossi G; Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.
Falesiedi M; Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.
Musumeci F; Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.
Carbone A; Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.
Schenone S; Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 23; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Glioblastoma*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents*/chemistry
Brain Neoplasms*/pathology
Humans ; Tyrosine Kinase Inhibitors ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
Autorzy:
Huang HN; Department of Pathology, National Taiwan University Hospital Hsin-Chu Branch, No. 25, Ln. 442, Section 1, Jingguo Road, North Dist., Hsinchu 300195, Taiwan.; Department and Graduate Institute of Pathology, College of Medicine, National Taiwan University, No. 1 Jen Ai Road Section 1, Taipei 100225, Taiwan.
Hung PF; National Institute of Cancer Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan 350401, Taiwan.
Chen YP; National Institute of Cancer Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan 350401, Taiwan.
Lee CH; National Institute of Cancer Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan 350401, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 23; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Humans ; Gefitinib/pharmacology ; Gefitinib/therapeutic use ; Adaptor Proteins, Vesicular Transport ; Leucine Zippers ; Quinazolines/pharmacology ; Quinazolines/therapeutic use ; ErbB Receptors/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Cell Line, Tumor ; Mutation ; Drug Resistance, Neoplasm ; Nuclear Proteins/metabolism ; Tumor Suppressor Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics.
Autorzy:
Lee CY; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
The M; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Meng C; Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), Technical University of Munich, Freising, Germany.
Bayer FP; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Putzker K; Chemical Biology Core Facility, EMBL Heidelberg, Heidelberg, Germany.
Müller J; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Streubel J; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Woortman J; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Sakhteman A; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Resch M; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Schneider A; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Wilhelm S; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
Kuster B; Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany. .; Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), Technical University of Munich, Freising, Germany. .; German Cancer Consortium (DKTK), partner site Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany. .
Pokaż więcej
Źródło:
Molecular systems biology [Mol Syst Biol] 2024 Jan; Vol. 20 (1), pp. 28-55. Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Journal Article
MeSH Terms:
Sarcoma*/drug therapy
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Proteomics/methods ; Proteome ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAF .
Autorzy:
Hassan AA; Chemistry Department, Faculty of Science, Organic Division, Minia University, Minia 61519, Egypt.
Mohamed NK; Chemistry Department, Faculty of Science, Organic Division, Minia University, Minia 61519, Egypt.
Aly AA; Chemistry Department, Faculty of Science, Organic Division, Minia University, Minia 61519, Egypt.
Ramadan M; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
Gomaa HAM; Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka 72341, Aljouf, Saudi Arabia.
Abdel-Aziz AT; Chemistry Department, Faculty of Science, Organic Division, Minia University, Minia 61519, Egypt.
Youssif BGM; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Bräse S; Institute of Organic Chemistry, Karlsruher Institut fur Technologie, 76131 Karlsruhe, Germany.
Fuhr O; Institute Karlsruhe of Nanotechnology (INT) and Karlsruhe Nano Micro Facility (KNMFi), Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Dec 05; Vol. 28 (24). Date of Electronic Publication: 2023 Dec 05.
Typ publikacji:
Journal Article
MeSH Terms:
Thiazoles*/chemistry
Antineoplastic Agents*/pharmacology
Humans ; Proto-Oncogene Proteins B-raf ; Molecular Docking Simulation ; Neoplasm Recurrence, Local ; ErbB Receptors ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Cell Line, Tumor ; Cell Proliferation ; Drug Screening Assays, Antitumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
Autorzy:
Yin L; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People's Republic of China.; Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People's Republic of China.
Xu J; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People's Republic of China.; Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People's Republic of China.
Wu W; Medical Record and Statistical Office, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.
Niu M; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People's Republic of China.; Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People's Republic of China.
Li Z; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People's Republic of China.; Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People's Republic of China.
Zhu F; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People's Republic of China.; Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People's Republic of China.
Xu K; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People's Republic of China.; Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2224625.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology
Humans ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; STAT5 Transcription Factor/genetics ; STAT5 Transcription Factor/metabolism ; Drug Resistance, Neoplasm/genetics ; Apoptosis ; K562 Cells ; Fusion Proteins, bcr-abl/genetics ; Fusion Proteins, bcr-abl/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; STAT3 Transcription Factor/genetics ; STAT3 Transcription Factor/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of new pyridine-quinoline hybrids as competitive and non-competitive PIM-1 kinase inhibitors with apoptosis induction and caspase 3/7 activation capabilities.
Autorzy:
El-Miligy MMM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Abdelaziz ME; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Fahmy SM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Ibrahim TM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Abu-Serie MM; Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt).
Mahran MA; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Hazzaa AA; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2152810.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Quinolines*/pharmacology
Male ; Humans ; Proto-Oncogene Proteins c-pim-1/metabolism ; Proto-Oncogene Proteins c-pim-1/pharmacology ; Caspase 3/metabolism ; Molecular Docking Simulation ; Cell Line, Tumor ; Kinetics ; Caco-2 Cells ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/metabolism ; Pyridines/pharmacology ; Apoptosis ; Cell Proliferation ; Drug Screening Assays, Antitumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 2761

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies